Globus Medical, Inc. reported a 18.4% increase in worldwide net sales for the quarter ended June 30, 2025, reaching $745.3 million. GAAP net income was $202.8 million, with GAAP diluted earnings per share at $1.49 and non-GAAP diluted EPS at $0.86. US Spine business led growth, with US net sales up 20.3% and international net sales up 11.0%.

The company’s second-quarter results were highlighted by record quarterly non-GAAP earnings per share, driven by the Globus base business. They reaffirmed full-year 2025 revenue guidance of $2.80 to $2.90 billion and non-GAAP EPS of $3.00 to $3.30. Worldwide net sales increased by 18.4% over the same period in 2024, with U.S. net sales up 20.3%.

GAAP net income for the second quarter of 2025 was $202.8 million, an increase of 538.7% over the same period in the prior year. The GAAP net income increase was primarily driven by the bargain purchase gain of $110.6 million and a tax benefit of $34.8 million from the release of a valuation allowance on certain deferred tax assets. Non-GAAP diluted EPS for the quarter was $0.86, compared to $0.75 in the second quarter of 2024.

Net cash provided by operating activities was $77.9 million, with non-GAAP free cash flow at $31.3 million for the second quarter of 2025. The company’s long-term strategy includes new product launches, driving organic growth, competitive rep recruiting, and robotic account pull through. They are focused on finalizing integration efforts from recent M&A activity to demonstrate topline growth and financial prudence.

Globus Medical will hold a teleconference to discuss its second quarter 2025 results at 4:30 p.m. Eastern Time today. Participants can access the conference call live via webcast on the Investors page of Globus Medical’s website. The company remains dedicated to solving unmet clinical needs and advancing care throughout spine, orthopedic trauma, joint reconstruction, biomaterials, and enabling technologies. Additional information is available on their website.

Read more at GlobeNewswire: Globus Medical Reports Second Quarter 2025 Results